An interventional study of MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG in Major Depressive Disorder (MDD), Treatment Resistant Depression and Major Depression, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 22 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Depressive Disorder, Major by Mayo Clinic — 3 open to participants now, 5 under way, none of them phase 3. Depressive Disorder, Major · Mayo Clinic.
Among the 14 studies in Depressive Disorder, Major by Mayo Clinic, this one is the only one that started in 2026, is one of 6 with no phase, and was the 14th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →3 of the 14 studies in Depressive Disorder, Major by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 22 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 60 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 58 across the 9 interventional studies, 40 across the 5 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
1 of the studies in Depressive Disorder, Major by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Depressive Disorder, Major by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to see if an experimental treatment for depression called intermittent theta burst stimulation (iTBS), a form of transcranial magnetic stimulation (TMS) can be improved for better results using electroencephalography (EEG) recordings (brain waves) for individuals with Major Depressive Disorder (MDD).
This is a feasibility study to test a "closed-loop" procedure which guides the timing of this FDA-cleared form of TMS. Each participant will receive an active experimental treatment, and the timing of the TMS pulses will be at one of three phases in the brain wave of interest.
This is a randomized, double-blind, 3 arm trial with a parallel design. All patients will receive an FDA cleared form of TMS called intermittent theta burst (iTBS) but will be randomized to 1) Closed-loop TMS-EEG with stimulation bursts delivered at the trough of theta waves, 2) Closed- loop TMS-EEG with stimulation bursts delivered at the peak of theta waves or 3) Closed-loop TMS-EEG random phase TMS delivery (control stimulation). Patients in all 3 study arms will wear EEG caps and undergo similar procedures to facilitate blinding. Blinded clinical raters will collect depression symptom severity measures at screening, baseline, and weekly for 6 weeks followed by monthly follow-up visits for 3 months to assess for delayed responses to treatment. The iTBS will be delivered with a MagVenture Cool B70 coil and X100 stimulator. TBS treatment will be delivered once daily (5 days per week for 6 weeks) to the left DLPFC at 120% MT, 600 pulses per session. The Localite system will provide neuronavigation for treatment site localization with the participant's structural MRI or in patients that cannot obtain an MRI, the provided standard MNI atlas. Depressive symptom severity will be assessed weekly with the 17-item Hamilton Depression Rating Scale (HDRS), the Montgomery-Asberg Depression Rating Scale (MADRS), a patient-reported Patient Health Questionnaire (PHQ-9)55, and a Generalized Anxiety Disorder 7-time scale (GAD-7)56. Patients will continue to receive any standard clinical psychotherapy at the same frequency and will continue current psychotropic medications at the current dose consistently for the duration of the study. Clinical assessments visits will take place during the last treatment day (treatment 5) of every week for 6 weeks of treatment. Follow-up assessments will be collected in person or remotely (via zoom or telephone appointment) based on patient preference.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive EEG-guided intermittent theta burst stimulation (iTBS) delivered to the left dorsolateral prefrontal cortex (DLPFC). Stimulation bursts are synchronized to the peak of the participant's individual theta oscillations. Treatment is administered once daily, 5 days per week, for 6 weeks (30 sessions total).
Device: MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG
Participants receive EEG-guided iTBS delivered to the left DLPFC with stimulation bursts synchronized to the trough of individual theta oscillations. Treatment is administered once daily, 5 days per week, for 6 weeks (30 sessions total)
Device: MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG
Participants receive EEG-guided iTBS delivered to the left DLPFC with stimulation occurring at a random phase of theta oscillations. Treatment is administered once daily, 5 days per week, for 6 weeks (30 sessions total). This arm serves as the reference condition.
Device: MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG
The MagVenture TMS Therapy System is based on the use of intermittent theta burst stimulation, or iTBS. This novel TMS protocol delivers treatment in only 3 minutes and is based on a patterned TMS paradigm delivered to the left-dorsolateral prefrontal cortex (LDPFC) at 120% of resting motor threshold (MT). It consists of bursts of 3 pulses at 50 Hz, with bursts repeated at 5 Hz, in a duty cycle of 2s on, 8 s off, over 3 minutes and 9 seconds, and a total of 600 pulses. For peak or trough iTBS, stimulation will consist of 3 pulses at 50 Hz delivered at intervals of their individual theta rhythm (e.g. 200 msec for a 5Hz oscillation) followed by an 8 second rest period. The pulses will be aligned to either the peak or the trough of the theta rhythm at the beginning of each pulse train. The TMS therapy will be delivered to the Left DLPFC at 120% of resting motor threshold (MT) daily for 5 days per week, for 6 weeks.
Feasibility of closed-loop EEG guided iTBS in adult participants with MDD.
Participant retention and completion rate of 80% or more at 4 and 6 weeks of treatment in patients receiving closed-loop guided iTBS
Time frame: 6 weeks and 12 weeks post-treatment
Change in Hamilton Depression Rating Scale (HDRS-17)
Closed-loop iTBS delivered to the peak theta rhythm will have greater improvements in depressive symptom severity as assessed with the HDRS as compared to the participants in the trough (n=20) and random (n=20) delivered iTBS.
Time frame: Baseline through Week 18
Plan to share: No — Individual participant data (IPD) collected during this study will not be made publicly available.
Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 36 months is close to that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.